Home Metabolism PPAR agonist Clofibric Acid

research use only

Clofibric Acid PPAR agonist

Cat.No.S4207

Clofibric acid(Chlorofibrinic acid) is a PPARα agonist and hypolipidemic agent.
Clofibric Acid PPAR agonist Chemical Structure

Chemical Structure

Molecular Weight: 214.65

Jump to

Quality Control

Batch: S420701 DMSO]43 mg/mL]false]Ethanol]43 mg/mL]false]Water]Insoluble]false Purity: 99.8%
  • Cited in Nature Medicine for its top-tier quality
  • COA
  • NMR
  • HPLC
  • SDS
  • Datasheet
99.8

Solubility

In vitro
Batch:

DMSO : 43 mg/mL (200.32 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 43 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 214.65 Formula

C10H11ClO3

 Storage (From the date of receipt)
CAS No. 882-09-7 Download SDF Storage of Stock Solutions

Synonyms Chlorofibrinic acid Smiles CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl

Mechanism of Action

Targets/IC50/Ki
PPARα
In vitro

Clofibric acid increases CYP4A6 gene expression in RK13 cells transfected with PPAR-G with EC50 of 80 μM. Clofibric acid (1 mM) treatment for 4 days induces 500-fold increase of P450 4Al RNA and 280-fold increase of acyl-CoA oxidase and P450 2Bl RNA in hepatocytes, relative to control cultures. Clofibric acid (250 μM) induces up-regulation of genes involved in peroxisome proliferation and in cell proliferation as well as down-regulation of genes involved in apoptosis in hepatocytes of rodent. Clofibric acid treatment is able to cause up-regulation of L-fatty acid binding protein (L-FABP) gene in hepatocytes of both rodent and human origin. Clofibric acid also up-regulates genes expression of the cytosolic, microsomal, and mitochondrial pathways involved in fatty acid transport and metabolism in both rodent and human hepatocyte cultures, and increases genes level of the peroxisomal pathway of lipid metabolism in rodents. An up-regulation of hepatocyte nuclear factor 1α (HNF 1α) by Clofibric acid is observed in human hepatocyte cultures. Clofibric acid also dose-dependently inhibits cell proliferation of cultured OVCAR-3 and DISS cells derived from human ovarian cancer. Clofibric acid treatment increases the expression of carbonyl reductase, which promotes the conversion of prostaglandin E2 (PGE2) to PGF 2α.

In vivo

Clofibric acid (50 mg/kg) treatment 4 days by gavage induces both P450 4A and BFB expression in zones 3 and 2 of the liver acinus in rats. 300 mg/kg of Clofibric acid causes a strong staining of both proteins throughout the liver acinus. Clofibric acid (9,000 ppm) treatment in diet significantly suppresses the growth of OVCAR-3 tumors xenotransplanted s.c. (46%) and significantly prolongs the survival of mice with malignant ascites derived from DISS cells as compared with control. Clofibric acid treatment increases the expression of carbonyl reductase in vivo. Clofibric acid treatment decreases PGE2 level as well as vascular endothelial growth factor (VEGF) amount in both of OVCAR-3–tumor and DISS-derived ascites. Reduced microvessel density and induced apoptosis are in solid OVCAR-3 tumors treated by Clofibric acid.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/17431116/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map